In just concluded Meeting of Board of Directors, the Board Approved and considered the following items: 1. Unaudited (Standalone and Consolidated) Financial Statements for the Quarter ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.4 pts less than Nifty Microcap 250 and 4.9 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
The Board of Gennex Laboratories approved unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025 on November 14, 2025. Standalone revenue from operations grew about 18.8% year-on-year to Rs. 2,932.63 lakhs in Q2 (vs Rs. 2,468.59 lakhs), while H1 revenue rose ~19.4% to Rs. 5,496.63 lakhs. Standalone net profit for Q2 stood at Rs. 453.32 lakhs (~9% growth), and H1 net profit was Rs. 868.27 lakhs (up ~4.3%). On a consolidated basis, Q2 net profit was Rs. 551.15 lakhs and H1 net profit was Rs. 1,052.80 lakhs. The statutory auditor, R Pugalia & Co., issued what the company notes describe as an 'unmodified qualified review report.' The company operates in a single segment – bulk drugs manufacturing (Guaifenesin, Methocarbamol) – with exports to multiple countries including Vietnam, India, Colombia, Egypt and Mexico.
Revenue growth is steady but margins are under pressure as material costs rose faster than revenue, and H1 EPS dipped slightly. A major concern is the deeply negative operating cash flow (consolidated net cash used in operations of Rs. 8,416 lakhs in H1), driven by a sharp build-up in trade receivables and inventories, alongside a big jump in short-term and long-term borrowings — worth monitoring closely by shareholders.